当前位置: 首页 >> 检索结果
341. Effectiveness of an app-based walking program for obese patients with inflammatory bowel disease in Korea: a single-blind parallel-group randomized clinical trial.
作者: Young Jin Lee.;Eun Ja Kwon.;Da-In Park.;Sang Hyoung Park.;Sung Wook Hwang.;Byong Duk Ye.
来源: BMC Gastroenterol. 2025年25卷1期417页
Obesity in patients with inflammatory bowel disease (IBD) not only exacerbates symptoms but also interferes with treatment and leads to additional complications. Therefore, managing weight loss and preventing obesity are crucial. This study was designed to develop and implement a 10-week walking exercise program, facilitated by a mobile application, to evaluate its effectiveness in managing weight in obese IBD patients.
342. Helicobacter pylori is associated with less tumor-infiltrating lymphocytes and a poor prognosis in gastric cancer.
作者: Zetian Chen.;Zhijun Zhang.;Hongxin Huang.;Chen Lu.;Qingya Li.;Mengpei Yan.;Chengjun Zhu.;Sen Wang.;Hongda Liu.;Zekuan Xu.;Zheng Li.
来源: BMC Gastroenterol. 2025年25卷1期420页
Helicobacter pylori (H. pylori) is carcinogenic and has the potential to cause progressive gastric lesions and gastric cancer (GC), which also represents one of the essential constituents of the tumor microenvironment (TME) of GC. The infiltration and functional status of tumor-infiltrating lymphocytes (TILs) in the TME affect the anti-tumor function of the body. However, the impact of H. pylori on anti-tumor immunity and prognosis of GC is still unclear.
343. Association between the dietary index of gut microbiota and abnormal bowel symptoms in U.S. adults: a cross-sectional study based on NHANES 2007-2010.
作者: Sicheng Shen.;Huayi Feng.;Chuyue Wang.;Yingqi Yang.;Zhiyang Chen.;Xiaopeng Wang.;Jiacheng Li.
来源: BMC Gastroenterol. 2025年25卷1期419页
The Dietary Index of Gut Microbiota (DI-GM) is a newly developed measure for assessing diet quality in relation to the diversity of the gut microbiome. However, whether it is associated with the risk of chronic constipation and chronic diarrhea remains unclear.
344. A novel inflammatory biomarker in assessing disease activity in ulcerative colitis: gasdermin D.
作者: Osman Cagin Buldukoglu.;Serkan Ocal.;Serdar Akca.;Galip Egemen Atar.;Besir Kaya.;Muhammet Devran Isik.;Ozlem Koca.;Ferda Akbay Harmandar.;Yesim Cekin.;Ayhan Hilmi Cekin.
来源: BMC Gastroenterol. 2025年25卷1期418页
Ulcerative colitis (UC) is a chronic inflammatory disease with a worldwide prevalance of around 5 million patients. Assessment of disease activity is crucial in management of UC patients. Gasdermin D (GSDMD) is a protein which belongs to the gasdermin protein family and plays a role in inflammatory cell death, pyroptosis. GSDMD activation has been shown to be related to inflammatory states in a variety of disorders, including inflammatory bowel diseases. With this study, we aimed to reveal a potential new inflammatory serum marker for assessing disease activity and severity in UC patients in a non-invasive manner.
345. An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease.
作者: Jurij Hanžel.;Virginia Solitano.;Sudheer Kumar Vuyyuru.;Remo Panaccione.;Bruce E Sands.;Laurent Peyrin-Biroulet.;Silvio Danese.;Geert R D'Haens.;Raja Atreya.;Matthieu Allez.;Charles N Bernstein.;Peter Bossuyt.;Brian Bressler.;Robert V Bryant.;Benjamin L Cohen.;Jean-Frederic Colombel.;Ferdinando D'Amico.;Axel Dignass.;Marla Dubinsky.;Phillip Fleshner.;Richard B Gearry.;Stephen B Hanauer.;Ailsa L Hart.;Maia Kayal.;Torsten Kucharzik.;Peter L Lakatos.;Edouard Louis.;Fernando Magro.;Neeraj Narula.;Rupert W Leong.;Julián Panés.;Tim Raine.;Zhihua Ran.;Miguel D Regueiro.;Walter Reinisch.;Siddharth Singh.;A Hillary Steinhart.;Simon Travis.;Ryan C Ungaro.;C Janneke van der Woude.;Takayuki Yamamoto.;Vineet Ahuja.;David T Rubin.;Parambir S Dulai.;Linda J Cornfield.;Malcolm Hogan.;William J Sandborn.;Brian G Feagan.;Vipul Jairath.;Christopher Ma.
来源: Gastroenterology. 2025年
Approval of new therapies for inflammatory bowel disease (IBD) requires rigorously designed and well-executed randomized controlled trials (RCTs). Corticosteroids remain a cornerstone of IBD induction therapy, and many patients in trials are enrolled while taking corticosteroids. Despite this, approaches to corticosteroid management in RCTs have been highly heterogeneous, often differing from clinical practice. This negatively impacts patients' willingness to participate due to prolonged corticosteroid exposure and may potentially bias outcomes in the clinical trial. Our aim is to provide comprehensive standardized recommendations on key aspects of corticosteroid use in IBD clinical trials through a multiphase, international expert consensus, with a goal to help inform and standardize practice in future RCTs.
346. Adeno-associated Virus-mediated Silencing of Sox4 Leads to Long-Term Amelioration of Liver Phenotypes in Mouse Models of Alagille Syndrome.
作者: Duncan Fox.;Jun Xie.;Jennifer L Burwinkel.;Josh M Adams.;Kashish Chetal.;Marzieh Keivandarian.;Yaniv Faingelernt.;Sanjay Subramanian.;Mario F Lopez.;Anna L Peters.;Nathan Salomonis.;Neda Zarrin-Khameh.;Guangping Gao.;Stacey S Huppert.;Hamed Jafar-Nejad.
来源: Gastroenterology. 2025年
In patients with Alagille syndrome (ALGS), bile duct paucity often leads to severe cholestatic phenotypes for which liver transplantation remains the only definitive treatment. No Food and Drug Administration-approved mechanism-based strategies exist to enhance biliary development in ALGS or other diseases with bile duct paucity. We aimed to identify a therapeutic target to address this unmet need.
350. Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials.
作者: Ye Zhang.;Jie Chen.;Fenglian Yu.;Wenxiong Zhang.;Yingmei Zhong.
来源: BMC Gastroenterol. 2025年25卷1期416页
Neoadjuvant chemotherapy (NC) is a cornerstone in the management of resectable esophageal squamous cell carcinoma (ESCC). The integration of PD-1/PD-L1 inhibitors into NC (NIC) regimens has shown promise; however, its efficacy and safety remain uncertain. This meta-analysis aims to compare the potential risks and clinical benefits of NIC versus NC in patients with resectable ESCC based on randomized controlled trials (RCTs).
351. Association between C-reactive protein to lymphocyte ratio and gallstones: a cross-sectional study.
作者: Xiaoyang Sun.;Jie Lin.;Zhenao Wang.;Chenfang Zhang.;Kai Zhao.;Xuewen Zhang.;Jiyao Sheng.
来源: BMC Gastroenterol. 2025年25卷1期415页
Inflammation plays a key role in the development of gallstones, and the C-reactive protein to lymphocyte ratio (CLR) has been introduced as a promising biomarker for evaluating inflammatory processes. Nonetheless, its correlation with gallstone prevalence remains ambiguous. This study aims to evaluate the potential link between CLR levels and gallstone prevalence.
352. Association between the immune-inflammation index and the severity and clinical outcomes of patients with inflammatory bowel disease: a systematic review and meta-analysis.
作者: Peiji Li.;Yilin Wu.;Wei Xiong.;Jiahui Cao.;Mengyun Chen.;Zhaowei Yuan.;Wenxin Guo.;Bing Yang.
来源: BMC Gastroenterol. 2025年25卷1期414页
Existing studies have explored the association between immune-inflammatory indices and inflammatory bowel disease (IBD), but there is a lack of comprehensive evidence. This meta-analysis and systematic review seeks to synthesize the data of available clinical research and offer the latest and comprehensive evidence-based conclusions regarding whether these immune-inflammatory indices can effectively predict the severity, activity, and prognosis of IBD.
353. Efficacy of ACupuncTure in Irritable bOwel syNdrome (ACTION): A Multicenter Randomized Controlled Trial.
作者: Jing-Wen Yang.;Ling-Yu Qi.;Shi-Yan Yan.;Yan-Fen She.;Ying Li.;Li-Li Chi.;Hui Hu.;Li-Qiong Wang.;Chang-Chun Ji.;Bang-Qi Wu.;Zi-Tong Fu.;Shuang-Jing Li.;Na-Na Yang.;Yu Wang.;Cun-Zhi Liu.
来源: Gastroenterology. 2025年
Irritable bowel syndrome (IBS) affects 4.1% of the adult population, with many reporting ongoing symptoms despite first-line therapies. Acupuncture is widely used for IBS, but without sufficient evidence. We aimed to assess the efficacy of acupuncture in patients with diarrhea-predominant IBS (IBS-D).
354. A preliminary exploration of a predictive model and nomogram for the efficacy of compound digestive enzyme therapy based on serum (PGI, PGII, VIP, and PRDX1) in patients with functional dyspepsia.
This study aimed to explore the feasibility of constructing compound digestive enzyme therapeutic effect prediction model based on serum pepsinogen I (PGI), pepsinogen II (PGII), vasoactive intestinal peptide (VIP), and peroxidase 1 (PRDX1) in patients with functional dyspepsia (FD), and draw nomograms, to provide reference for the selection of clinical treatment.
355. A cooling off period: decline in the use of hot biopsy forceps technique in colonoscopy in the U.S. Medicare population 2000-2019.
作者: Andrew J Read.;Jacob E Kurlander.;Akbar K Waljee.;Sameer D Saini.
来源: BMC Gastroenterol. 2025年25卷1期411页
The use of hot biopsy forceps (with electrocautery) is no longer routinely recommended given increased complications compared to cold biopsy forceps (without electrocautery). It is unknown how often the technique is currently used in the United States (U.S.) or how its usage has changed over time.
356. Comparative efficacy of gelatin sponge, microcoils, and nbca in arterial gastrointestinal bleeding: a retrospective study.
Arterial gastrointestinal bleeding poses a serious threat to life that requires timely and effective intervention. This study evaluated the effectiveness of three different embolization strategies: the use of gelatin sponge alone, in combination with microcoils, and in combination with n-butyl cyanoacrylate (NBCA).
357. Relative fat mass and risk of metabolic dysfunction associated steatotic liver disease and severe hepatic steatosis in U.S. adults: analysis of NHANES 2017-2020 data.
作者: Jianjun Wang.;Wei He.;Xianfu Cai.;Zhaohui Hu.;Yonghai Peng.;Xi Chen.;Pei Yang.;Xintao Zeng.;Sirui Chen.;Decai Wang.
来源: BMC Gastroenterol. 2025年25卷1期410页
Relative fat mass (RFM) is a novel, easily calculated, and cost-effective index of fat content and distribution in the body, associated with the odds of developing various obesity-related diseases. However, its association with metabolic dysfunction associated steatotic liver disease (MASLD) and severe hepatic steatosis (SHS) is underexplored. This study aims to examine the relationship between RFM and the odds of having MASLD or SHS in the general adult population.
358. Development and validation of a new predictive model for the immune tolerance stage of chronic HBV infection based on the liver histopathological changes.
作者: Wentao Li.;Rui Huang.;Jian Wang.;Binhao Zhang.;Qiupeng Wang.;Jiang Feng.;Tongjing Xing.
来源: BMC Gastroenterol. 2025年25卷1期408页
To identify clinical and viral indicators for the development of a new model to accurately differentiate the stages of chronic hepatitis B virus (HBV) infection based on histopathological changes in the liver.
359. Comprehensive analysis of risk factors and nomogram development for predicting hepatic metastasis following radical resection of adenocarcinoma of the esophagogastric junction.
Adenocarcinoma of the esophagogastric junction (AEG) often presents with subtle early symptoms and delayed diagnosis, frequently resulting in liver metastasis and a poor prognosis. This study aimed to investigate the primary risk factors influencing postoperative liver metastasis in AEG and to develop a simple predictive model to facilitate clinical risk stratification and individualized follow-up strategies.
360. Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis.
Several studies revealed that synbiotics have been beneficial in managing non-alcoholic fatty liver disease (NAFLD), but the findings are conflicting. We aimed to assess the effect of synbiotic supplementation on cardiovascular risk factors in patients with NAFLD.
|